[go: up one dir, main page]

MX2011009669A - Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. - Google Patents

Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.

Info

Publication number
MX2011009669A
MX2011009669A MX2011009669A MX2011009669A MX2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A MX 2011009669 A MX2011009669 A MX 2011009669A
Authority
MX
Mexico
Prior art keywords
influence
excipients
pharmaceutical composition
controlled release
coating
Prior art date
Application number
MX2011009669A
Other languages
English (en)
Inventor
Michael Gottschalk
Hans Baer
Thomas Fuerst
Gerhard Renner
Thomas Rupp
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of MX2011009669A publication Critical patent/MX2011009669A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención trata sobre una composición farmacéutica de liberación controlada, que consta de un núcleo, que consta de un ingrediente farmacéutico activo, donde el núcleo está revestido por una capa de revestimiento que proporciona resistencia y que tiene el efecto de proporcionar el perfil de liberación del ingrediente farmacéutico activo para que sea resistente a la influencia del etanol, en donde la capa de revestimiento que proporciona resistencia al etanol consta de al menos 70% por peso de una mezcla de una porción polimérica a) y una porción de excipientes b), donde la porción polimérica a) está presente en una cantidad de al menos 3.0% por peso calculada en el peso del núcleo y donde la porción polimérica a) consta de una mezcla de polímeros a1) y a2) con a1) 60 a 99% por peso, con base en el peso en seco de la mezcla polimérica, de un polímero de vinilo o un copolímero de vinilo esencialmente neutral insoluble en agua, y a2) 1 a 40% por peso, con base en el peso seco de la mezcla polimérica, de un copolímero amino (met) acrilato, que es soluble en un medio acuoso amortiguado hasta de ph 4.0 e insoluble al menos por encima de ph 5.0 y la porción de excipientes b) que consta de los excipientes b1) 60 a 250% por peso de un lubricante inerte no poroso b2) 0.1 a 25% por peso de un emulsionante y además o de manera alternativa a b2) b3) 0.1 a 30% por peso de un plastificante y de forma opcional b4) 1 - 35% por peso de un compuesto celulósico. donde los excipientes de la porción de excipientes b) se calculan en peso en seco de la porción polimérica a).
MX2011009669A 2009-03-18 2009-03-18 Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes. MX2011009669A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/053177 WO2010105673A1 (en) 2009-03-18 2009-03-18 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients

Publications (1)

Publication Number Publication Date
MX2011009669A true MX2011009669A (es) 2011-12-14

Family

ID=40752823

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009669A MX2011009669A (es) 2009-03-18 2009-03-18 Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.

Country Status (10)

Country Link
US (1) US20110311631A1 (es)
EP (1) EP2408437A1 (es)
JP (1) JP5619131B2 (es)
KR (1) KR20120003436A (es)
CN (1) CN102365083A (es)
BR (1) BRPI0924427A2 (es)
CA (1) CA2755814A1 (es)
IL (1) IL214612A0 (es)
MX (1) MX2011009669A (es)
WO (1) WO2010105673A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112709A1 (en) * 2010-03-09 2011-09-15 Elan Pharma International Limited Alcohol resistant enteric pharmaceutical compositions
SG184523A1 (en) 2010-05-10 2012-11-29 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
RU2606588C2 (ru) * 2011-06-17 2017-01-10 Эвоник Рем ГмбХ Композиция покрытия, подходящая для фармацевтических или нутрицевтических дозированных форм
KR101799625B1 (ko) 2011-06-17 2017-11-20 에보니크 룀 게엠베하 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물
JP6099638B2 (ja) 2011-06-17 2017-03-22 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングEvonik Roehm GmbH エタノールの影響に耐性のある胃液抵抗性の医薬又は栄養補助組成物
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
CA2877774C (en) 2012-07-12 2017-07-18 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
EP2945994B1 (en) 2013-01-18 2018-07-11 Basf Se Acrylic dispersion-based coating compositions
JP6150564B2 (ja) * 2013-03-08 2017-06-21 杏林製薬株式会社 口腔内速崩壊性錠剤
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
SG11201602884WA (en) 2013-11-13 2016-05-30 Euro Celtique Sa Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド 徐放性乱用抑止性液体充填剤形
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10722471B2 (en) * 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106727435B (zh) * 2016-12-26 2020-06-02 浙江工业大学 一种美托洛尔缓释胶囊及其制备方法
US11554114B2 (en) * 2017-03-31 2023-01-17 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredients
US20200289423A1 (en) 2017-09-14 2020-09-17 Evonik Operations Gmbh Polymer and dosage form with sustained release properties and resistance against the influence of ethanol
EP3727384A4 (en) 2017-12-20 2021-11-03 Purdue Pharma L.P. ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES
KR20200130369A (ko) 2018-03-09 2020-11-18 에보니크 오퍼레이션즈 게엠베하 에탄올의 영향에 대한 내성을 갖는 중합체 혼합물
KR102138253B1 (ko) * 2018-08-17 2020-07-29 한국유나이티드제약 주식회사 실로스타졸 서방성 제제
KR20210094513A (ko) * 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
CN112294777B (zh) * 2020-11-04 2022-07-05 南京康川济医药科技有限公司 一种盐酸伊伐布雷定缓释制剂及其制备方法和应用
WO2023280962A1 (en) * 2021-07-09 2023-01-12 Evonik Operations Gmbh Composition comprising a (meth)acrylate copolymer, an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid and specific glidants
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法
WO2023224097A1 (ja) * 2022-05-18 2023-11-23 東和薬品株式会社 膜形成用組成物、膜状組成物及びその利用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
AU5775398A (en) * 1996-12-17 1998-07-15 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
US6524620B2 (en) * 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
DE19918435A1 (de) * 1998-07-23 2000-01-27 Roehm Gmbh Überzugs- und Bindemittel für orale oder dermale Arzneiformen
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
MXPA05002623A (es) * 2002-09-09 2005-05-05 Biovail Lab Inc Formulaciones cronoterapeuticas de diltiazem y la administracion de las mismas.
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
RU2372893C2 (ru) * 2003-10-31 2009-11-20 Хексал Аг Содержащий фармацевтический агент состав с покрытием
AU2006208627B8 (en) * 2005-01-28 2009-08-13 Mundipharma Pty Limited Alcohol resistant dosage forms
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
RU2433817C2 (ru) * 2006-01-21 2011-11-20 Эбботт Гмбх Унд Ко.Кг Лекарственная форма и способ для доставки вызывающих зависимость лекарственных веществ
DE102006051020A1 (de) * 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
PL2187873T3 (pl) * 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
PL2187876T3 (pl) * 2007-09-21 2013-01-31 Evonik Roehm Gmbh Farmaceutyczna kompozycja opioidowa o zależnym od pH kontrolowanym uwalnianiu z odpornością przed wpływem etanolu

Also Published As

Publication number Publication date
CN102365083A (zh) 2012-02-29
US20110311631A1 (en) 2011-12-22
IL214612A0 (en) 2011-09-27
BRPI0924427A2 (pt) 2016-01-26
KR20120003436A (ko) 2012-01-10
JP2012520832A (ja) 2012-09-10
WO2010105673A1 (en) 2010-09-23
JP5619131B2 (ja) 2014-11-05
CA2755814A1 (en) 2010-09-23
EP2408437A1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
MX2011009669A (es) Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante un revestimiento compuesto de una mezcla polimérica y excipientes.
MX2011009667A (es) Composición farmacéutica de liberación controlada con resistencia a la influencia de etanol mediante el uso de un revestimiento compuesto de polímeros de vinilo neutrales y excipientes.
MX347227B (es) Composicion farmaceutica o nutraceutica con liberacion sostenida caracteristica y con resistencia contra la influencia del etanol.
WO2010064126A3 (en) Controlled release dosage forms
MX355662B (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influencia de etanol.
WO2012085043A3 (en) Rapidly disintegrating, solid coated dosage form
BRPI0720626A2 (pt) Composição formadora de película, nanopartículas modificadas, revestimento resistente a risco, usos de um copolímero segmentado, e de nanopartículas modificadas
MX2016010437A (es) Composicion farmaceutica o nutraceutica con caracteristica de liberacion sostenida y con resistencia contra la influencia del etanol.
WO2010005726A3 (en) Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
NZ600123A (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
WO2011106416A3 (en) Abuse-resistant formulations
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
WO2012034079A3 (en) Macrolide dosage forms
IL203901A (en) Opioid-controlled controlled-release drug - with high alcohol resistance, process, preparation and use
MX376383B (es) Composicion farmaceutica o nutraceutica con resistencia contra la influencia del etanol
BR112014002837A2 (pt) dispersão aquosa com baixo teor de formaldeído de um copolímero de vinil éster/etileno preparado por meio de copolimerização de emulsão de uma mistura de monômero; composição de adesivo; produto de cigarro; e uso da composição de adesivo
WO2010106314A3 (en) Formulation comprising avermectin particles coated with a photo - protecting agent
WO2011053003A3 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
EP3856806A4 (en) AQUEOUS POLYMER DISPERSION AND AQUEOUS COATING COMPOSITION THEREOF
WO2009121970A3 (de) Schichtmaterial
WO2010005732A3 (en) Composition and method of preparation of release systems for constant (zero-order) release of active agents
WO2014106116A3 (en) Therapeutic compositions comprising antibodies
BR112013027484A8 (pt) Composição farmacêutica ou nutracêutica com resistência gástrica, e uso de um polímero de (met)acrilato
WO2013012666A3 (en) Compounds, methods of making, and methods of use
BR112012022363A2 (pt) forma de dosagem com liberação modificada

Legal Events

Date Code Title Description
FG Grant or registration